MBrace Ther­a­peu­tics cap­i­tal­izes on ADC wave with $85M Se­ries B to en­ter the clin­ic this quar­ter

MBrace Ther­a­peu­tics has raised an $85 mil­lion Se­ries B for a Phase I clin­i­cal tri­al of its first an­ti­body-drug con­ju­gate as in­vestors and Big Phar­mas pump bil­lions of dol­lars in­to AD­Cs, a type of can­cer treat­ment that has bal­looned from a niche of on­col­o­gy R&D to a cen­ter­piece of in­dus­try deal­mak­ing.

The San Diego-based biotech, which is born out of re­search from a Rut­gers Uni­ver­si­ty wife-and-hus­band duo, has two AD­Cs in the works, CEO Isan Chen told End­points News. The start­up is go­ing af­ter new tar­gets with AD­Cs rather than try­ing to be a fast fol­low­er or a me-too type of com­pa­ny try­ing to make the next TROP2-, Nectin4- or HER2-tar­get­ed can­cer treat­ment, the CEO added.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER